OneOme Using genetics to optimize medications

Co-founded by Mayo Clinic, OneOme is a full-service PGx partner that helps organizations unlock the power of precision medicine.

The cost of adverse drug events (ADEs)

Each year, adverse drug events result in a tremendous negative impact on patient lives and the U.S. health system.

THE ANNUAL
IMPACT OF
ADVERSE DRUG
EVENTS



2.2 million hospital admissions¹



\$136 billion in healthcare costs¹



4th leading cause of death for Americans¹

Personalized prescribing with pharmacogenomics

Because the effect of drugs can vary based on genetics, clinicians can use pharmacogenomic (PGx) testing to help make more informed medication decisions for individual patients, based on their unique DNA.



90% of the general population has a gene variant that may affect observed medication variability^{2,3}



24% of participants have been prescribed a drug for which they are predicted to have an atypical response⁴





RightMed for Populations builds on the science of PGx to help you maximize the benefits of more personalized medication decisions at the organizational level.

We partner with you to develop scalable, evidence-based solutions that span therapeutic areas and patient populations — so that you can truly unlock the power of precision medicine.

Powering PGx programs of any size, ranging from an initial PGx pilot to population-level PGx initiatives.



Assessment

Evaluation of patient populations to identify who will benefit most significantly from PGx testing



Analysis

End-to-end PGx testing and analysis, including patient DNA testing, personalized PGx results reporting, and clinical decision support

CLINICAL DECISION SUPPORT & OTHER SERVICES



Vantage clinical decision support



EHR integration with real-time alerts



PGx program implementation & support



PGx training & education



Clinical consults

Elevate your precision medicine initiative with RightMed for Populations®



OneOme.com

+1 844-663-6635

Support@OneOme.com

REFERENCES

- 1. American Society of Pharmacovigilance. Pharmacovigilance. Retrieved 2021, from https://stopadr.org.
- 2. Van Driest SL, et al. Clin Pharmacol Ther. 2014;95(4):423-431.
- 3. Yuan J, et al. Jmol Diag. 2016;18(3):438-445.
- 4. McInnes G, et al. Pharmacogenetics at scale: an analysis of the UK biobank. Clin Pharmacol Ther. 2021;109:1528-1537.